Solution for deep, hard-to-heal wounds with additional contouring functionality
Columbia, MD – (February 3, 2014 ) – ACell, Inc., a leading regenerative medicine company focused on the development, manufacturing and commercialization of tissue repair products, today announced that it has launched the new MatriStem® Multilayer Wound Matrix device for deep, hard-to-heal, full-thickness wounds. The 1:1 mesh design of MatriStem Multilayer Wound Matrix is built to accommodate moderate to heavy wound exudate and provides effective contouring functionality in wound application.
MatriStem products are medical devices that maintain and support a healing environment through constructive remodeling. Comprised of naturally-occurring urinary bladder matrix (UBM), MatriStem maintains an intact epithelial basement membrane which is hypothesized to facilitate the body’s natural healing potential.
The MatriStem Multilayer Wound Matrix device is easy to prepare, apply and fixate and requires no special handling or storage requirements. MatriStem Multilayer Wound Matrix is appropriate for both acute and chronic wounds.
Jim DeFrancesco, Chief Executive Officer and Board Director, remarked, “ACell has developed MatriStem Multilayer Wound Matrix to address an unmet need in the area of acute and chronic wound care management. The launch of this new product provides a new option for physicians treating patients suffering from deep, hard-to-heal wounds.”
MatriStem devices have received multiple 510(k) clearances from the FDA and are indicated for wound management including for pressure ulcers, venous ulcers, diabetic ulcers, surgical wounds and trauma wounds, and the reinforcement of soft tissue where weakness exists in urological, gynecological and gastroenterological anatomy.
ACell, Inc. offers the next generation of regenerative medicine through the development and commercialization of unique extracellular matrix products to repair and remodel damaged tissues in a broad range of applications. Its patented MatriStem ECM medical devices maintain and support a healing environment through constructive remodeling and are available in particle and sheet forms for the treatment of acute wounds and various surgical procedures. For more information please visit www.acell.com.
ACell, Inc. is a leading developer, manufacturer and marketer of next-generation regenerative medicine products. Its products are cleared for a variety of indications and are marketed under the brand name “MatriStem.” A privately held Company, Acell produces MatriStem in its manufacturing facilities and markets its products to physicians in the U.S. through a national direct sales force. For more information, call (800) 826-2926 or visit www.acell.com.
MatriStem Products consist of porcine-derived extracellular matrix (ECM) that maintain and support a healing environment through constructive remodeling, and are available in particle and sheet forms by prescription only. These devices, trademarked as MatriStem, are appropriate for acute wounds, chronic wounds and various surgical procedures. All MatriStem devices are made in the USA. Refer to IFU supplied with each device for indications, contraindications, and precautions.Return to News